Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Arthroscopic Debridement Ineffective in Patients with Knee Osteoarthritis

By HospiMedica staff writers
Posted on 11 Feb 2008
Arthroscopic debridement (AD) is not effective for reducing pain and improving function in patients with osteoarthritis (OA) of the knee, according to the results of a new study.

Researchers from Khon Kaen University (Khon Kaen, Thailand) searched the Cochrane Central Register of Controlled Trials (CENTRAL), Medline (1966 - 2006), Cinhal (1982 - 2006), Embase (1988 - 2006), and Web of Science (1900 - 2006), as well as the bibliographies, reference lists, and cited web sites of identified papers. More...
Selection criteria were randomized controlled trial or controlled clinical trial design; comparison of efficacy of AD versus another surgical procedure, including sham or placebo surgery and other nonsurgical interventions; and participants diagnosed with primary or secondary knee OA without other joint involvement or conditions requiring long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs). Pain relief and improved function of the knee were the primary endpoints.

The three randomized controlled trials included in the review enrolled 271 patients. The first trial comparing AD with lavage and sham surgery, and found there was no significant difference compared to lavage. However, when compared with sham surgery, outcomes for AD were worse at 2 weeks and not significantly different at two years. The second randomized controlled trial compared AD with arthroscopic washout and showed that AD significantly reduced knee pain at five years compared to washout. In the third randomized controlled trial there was no significant difference for AD compared to closed-needle lavage. The study was published online in the January 23, 2008, issue of the Cochrane Database of Systematic Reviews.

"There is 'gold' level evidence that AD has no benefit for undiscriminated OA,” concluded lead author Wiroon Laupattarakasem, M.D., and colleagues. "Observational studies have shown benefits for arthroscopic debridement on the osteoarthritic knee, but other recent studies have yielded conflicting results that suggest AD may not be effective.”

Knee OA begins with deterioration of the articular cartilage. Primary OA of nonspecific cause generally has slower progression versus secondary OA, which has a definite cause.
One treatment option for OA is AD, which involves irrigation to remove debris and mechanical shaving or removal of loose or misshapen parts of the joint.


Related Links:
Khon Kaen University

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.